A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

ABSTRACT: This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms,Gastroesophageal Cancer

PROVIDER: 2287946 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR